Blinding

Blinding means keeping knowledge of the assigned treatment from one or more groups in a trial: the participant, the treating clinician, the outcome assessor, the statistician. Its purpose is to stop expectation feeding back into the data, whether through the participant reporting symptoms differently or the assessor grading an ambiguous scan in the direction they hope for. Reporting standards now ask trials to name which groups were blinded, because the labels single, double and triple blind carry no consistent meaning.

Blinding is hardest to maintain where the drug announces itself. Metabolic peptide trials are a clear case, since substantial nausea in the first weeks and visible weight change over months tell many participants which arm they are in. This is why placebo arms are matched for appearance, injection volume and schedule, and why some trials formally test blinding by asking participants at the end which treatment they think they received.

What blinding buys depends on the endpoint. For all-cause mortality or a value read by an automated analyser, unblinding matters little. For pain, fatigue, sleep quality, cognitive testing and dermatological appearance it can account for a large share of the apparent effect, and a trial that cannot blind participants can usually still blind the assessor.

The error to avoid is reading double-blind as a guarantee that nobody knew, since functional unblinding through side effects is common and rarely reported. The mirror-image error is dismissing every unblinded finding, when for objective endpoints an open-label design may be adequate. The useful question is which endpoint was measured, by whom, and what that person could infer at the moment of measurement.